AFP and hepatocellular carcinoma: In particular, although AFP is currently used as the first biomarker for identifying HCC patients most likely to receive the survival benefits of ramucirumab therapy [35], the molecular mechanism underlying the correlation of expression status of AFP with the anti-tumor effects of VEGFR2 blockade remains unclear.